New data for investigational gene editing program presented at EHA
Vertex and CRISPR Therapeutics share new clinical data on investigational potential treatments for severe sickle cell disease and transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Annual Meeting
U.S. FDA Approves Expanded Indication for Our Fourth Cystic Fibrosis Medicine
View our 2020 Corporate Responsibility Report
Read more about how we continued to operate as a responsible business, supported our communities and drove lasting social and environmental change in 2020.
Type 1 Diabetes Cell Therapy Program Receives Fast Track Designation and Initiates Phase 1/2 Clinical Trial
We announced that the U.S. FDA granted us Fast Track Designation and that we’ve opened our Phase 1/2 clinical trial for our investigational cell therapy for the treatment of type 1 diabetes.
Featured contents
We Are Vertex